Gastrointestinal and Pancreatic Manifestations of Cystic Fibrosis in the Era of Highly Effective Modulators.

This review synthesizes emerging evidence on gastrointestinal (GI) disorders, specifically luminal and pancreatic function in the era of triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Elexacaftor-tezacaftor-ivacaftor has been associated with mild improvements in GI symptoms and disease burden in patients' reported outcomes and has shown a significant increase in growth and body mass index reflecting improved nutritional status, even among individuals who remain pancreatic insufficient. Long-term data on triple CFTR modulators remain limited, highlighting the need to understand their long-term impact on GI manifestations, as survival improves and chronic intestinal inflammation persists.